Slowing sales, mega-mergers, generic implosions and whipsawing exchange rates have caused some shakeups within the Top 20 Pharma ranks. The loss of Wyeth and Schering-Plough, coupled with Roche’s defection to the Biopharma list, led us to find several new players: Otsuka, Gilead and Mylan.
I’m not sure how significant it is that half of “the second tier” (companies 11-20) are based in Japan, but I find it interesting that Gilead (#19) is the only non-generic U.S. pharma company in that tier. (Just below the cutoff line, companies #21 and #22 are Dutch and Japanese, respectively.) I also find it interesting that Teva has revenue goals that could propel it into the top 7 ranks in the next few years. Aim high, pharma!
—Gil Y. Roth, Editor
|Top 20 Pharmaceutical Companies|
|06||Merck & Co.||$26,929|
|07||Johnson & Johnson||$22,520|
|08||Eli Lilly & Co.||$20,629|
|11||Takeda Chem. Ind.||$14,204|
Based on 2009 pharma revenues.
Note: In all Top Company profiles, dollar amounts are in millions.
Editor: Gil Y. Roth
Associate Editor: Kristin Brooks
Contributing Editor: Derek B. Lowe
All profiles written by Gil Roth, except Astellas and Daiichi-Sankyo, by Kristin Brooks.
The Lowe Down capsules written by Derek Lowe
All pipeline information compiled by Kristin Brooks
Sales information compiled by Gil Roth
Back to the July/August 2010 issue